Innoviva, Inc. (INVA) is a Healthcare stock trading at $21.08 (as of 2026-08-21), with a market capitalization of $1.52B and a trailing P/E of 4.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Innoviva develops and commercializes specialty pharmaceuticals, and it makes money primarily through royalties tied to net sales of products such as RELVAR/BREO ELLIPTA and ANORO ELLIPTA, plus its own net product sales and licensing revenue.
The profit engine is royalty revenue tied to partners' global net sales of its key inhaled medicines (RELVAR/BREO ELLIPTA and ANORO ELLIPTA), supplemented by Innoviva's smaller net product sales and license revenue.
| Relvar/Breo R | $0.1B |
| Anoro R | $0.0B |
| Prod+Lic | $0.0B |
| Other | $0.0B |
Business quality (Strong): Clear operating visibility into royalty revenue and product or licensing revenue, but the segment breakdown provided here does not fully reconcile the remaining revenue, limiting how precisely investors can decompose total sales.
Valuation: At 4× earnings, INVA trades 79% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $21.08 |
| Market Cap | $1.52B |
| P/E Ratio | 4.0 |
| EV / EBITDA | 7.5 |
| Price / Book | 1.23 |
| Price / Sales | 3.60 |
| FCF Yield | 19.5% |
| DCF Value (model) | $39.06 |
| DCF Upside vs Price | 85.3% |
| Revenue (TTM) | $411.33M |
| Net Margin | 65.9% |
| Revenue Growth (YoY) | 14.7% |
| EPS Growth (YoY) | 986.5% |
| FCF Growth (YoY) | 3.9% |
| Altman Z-Score | 3.34 (safe) |
| Stock P/E | 4.0 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -81.5% |
| vs Industry | -76.6% |
| Top Institutional Holder | BlackRock, Inc. ($263.47M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 2 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Pavel Raifeld |
| Employees | 127 |
| Country | US |
| IPO Date | 2004-10-05 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.